Adaptimmune Therapeutics (ADAP)
NASDAQ: ADAP
· Real-Time Price · USD
0.28
0.01 (2.04%)
At close: May 23, 2025, 3:59 PM
0.29
3.32%
After-hours: May 23, 2025, 05:56 PM EDT
2.04% (1D)
| Bid | 0.25 |
| Market Cap | 72.12M |
| Revenue (ttm) | 179.64M |
| Net Income (ttm) | -69.89M |
| EPS (ttm) | -0.3 |
| PE Ratio (ttm) | -0.93 |
| Forward PE | -1.96 |
| Analyst | Buy |
| Ask | 0.29 |
| Volume | 381,694 |
| Avg. Volume (20D) | 1,989,076 |
| Open | 0.27 |
| Previous Close | 0.27 |
| Day's Range | 0.26 - 0.28 |
| 52-Week Range | 0.20 - 1.48 |
| Beta | 2.85 |
About ADAP
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ADAP
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ADAP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Adaptimmune Therapeutics has released their quartely earnings
on May 13, 2025:
1 week ago
-15.31%
ADAP stock has given up its prior gain. Adaptimmun...
Unlock content with
Pro Subscription
1 week ago
-15.31%
Adaptimmune Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.
2 months ago · seekingalpha.com
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call TranscriptAdaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2024 Earnings Conference Call March 20, 2025 8:00 AM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Cintia Piccina - Chief Commercial Of...
